Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (291-300 of 379) with videos related to

Pageof 38
Sort By:
JAMA Oncology|December 8, 2022
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without IpilimumabJennifer L McQuade, Hans Hammers, Helena Furberg, et al.
German Medical Science : GMS E-Journal|June 24, 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisKatrin Patrij, Marcel Reiser, Luise Wätzel, et al.
Leukemia & Lymphoma|December 24, 2015
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study GroupStephanie Sasse, Magdalena Alram, Horst Müller, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|August 16, 2021
Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study groupBoris Böll, Helen Goergen, Nils Arndt, et al.
Haematologica|January 29, 2016
The European Hematology Association Roadmap for European Hematology Research: a consensus documentAndreas Engert, Carlo Balduini, Anneke Brand, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Pageof 38

Showing results (291-300 of 379) with videos related to

Sort By:
Pageof 38
JAMA Oncology|December 8, 2022
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without IpilimumabJennifer L McQuade, Hans Hammers, Helena Furberg, et al.
German Medical Science : GMS E-Journal|June 24, 2011
Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysisKatrin Patrij, Marcel Reiser, Luise Wätzel, et al.
Leukemia & Lymphoma|December 24, 2015
Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study GroupStephanie Sasse, Magdalena Alram, Horst Müller, et al.
The Lancet. Oncology|September 11, 2016
Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study GroupStefanie Kreissl, Horst Mueller, Helen Goergen, et al.
British Journal of Haematology|August 16, 2021
Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study GroupDennis A Eichenauer, Ina Bühnen, Stefanie Kreissl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2013
Relapsed hodgkin lymphoma in older patients: a comprehensive analysis from the German hodgkin study groupBoris Böll, Helen Goergen, Nils Arndt, et al.
Haematologica|January 29, 2016
The European Hematology Association Roadmap for European Hematology Research: a consensus documentAndreas Engert, Carlo Balduini, Anneke Brand, et al.
Blood|April 9, 2008
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trialAnton Hagenbeek, Ole Gadeberg, Peter Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
Pageof 38